Molecular Characterisation of the Synovial Fluid Microbiome in Rheumatoid Arthritis Patients and Healthy Control Subjects
Overview
Affiliations
Methods: The presence and identity of bacterial and fungal DNA in the synovial fluid of rheumatoid arthritis (RA) patients and healthy control subjects was investigated through amplification and sequencing of the bacterial 16S rRNA gene and fungal internal transcribed spacer region 2 respectively. Synovial fluid concentrations of the cytokines IL-6, IL-17A, IL22 and IL-23 were determined by ELISA.
Results: Bacterial 16S rRNA genes were detected in 87.5% RA patients, and all healthy control subjects. At the phylum level, the microbiome was predominated by Proteobacteria (Control = 83.5%, RA = 79.3%) and Firmicutes (Control = 16.1%, RA = 20.3%), and to a much lesser extent, Actinobacteria (Control = 0.2%, RA = 0.3%) and Bacteroidetes (Control = 0.1%, RA = 0.1%). Fungal DNA was identified in 75% RA samples, and 88.8% healthy controls. At the phylum level, synovial fluid was predominated by members of the Basidiomycota (Control = 53.9%, RA = 46.9%) and Ascomycota (Control = 35.1%, RA = 50.8%) phyla. Statistical analysis revealed key taxa that were differentially present or abundant dependent on disease status.
Conclusions: This study reports the presence of a synovial fluid microbiome, and determines that this is modulated by disease status (RA) as are other classical microbiome niches.
Potential role of gut-related factors in the pathology of cartilage in osteoarthritis.
Ning P, Lin S, Shi Y, Liu T Front Nutr. 2025; 11():1515806.
PMID: 39845920 PMC: 11753001. DOI: 10.3389/fnut.2024.1515806.
Maimaiti Z, Liu L Infect Drug Resist. 2024; 17:5557-5566.
PMID: 39691489 PMC: 11651062. DOI: 10.2147/IDR.S482931.
Unveiling the Potential of Probiotics in Osteoarthritis Management.
Karim A Curr Rheumatol Rep. 2024; 27(1):2.
PMID: 39579259 DOI: 10.1007/s11926-024-01166-5.
Gut microbiota and autoimmune diseases: Insights from Mendelian randomization.
Mu F, Rusip G, Florenly F FASEB Bioadv. 2024; 6(11):467-476.
PMID: 39512840 PMC: 11539032. DOI: 10.1096/fba.2024-00037.
Bonanzinga T, Conte P, Anzillotti G, Longobardi V, Kon E, Rescigno M EFORT Open Rev. 2024; 9(10):969-979.
PMID: 39360783 PMC: 11457803. DOI: 10.1530/EOR-23-0191.